Welcome to the all-new Vetlearn

  • Vetlearn is getting a new home. Starting this fall,
    Vetlearn becomes part of the NAVC VetFolio family.

    You'll have access to the entire Compendium and
    Veterinary Technician archives and get to explore
    even more ways to learn and earn CE by becoming
    a VetFolio subscriber. Subscriber benefits:
  • Over 500 hours of interactive CE Videos
  • An engaging new Community for tough cases
    and networking
  • Three years of NAVC Conference Proceedings
  • All-new articles (CE and other topics) for the entire
    healthcare team

To access Vetlearn, you must first sign in or register.

registernow

  • Registration for new subscribers will open in August 2014!
  • Watch for additional exciting news coming soon!
Become a Member

Reference Desk June 2012

Foot and Mouth Vaccine Receives Conditional USDA Approval for Use in Cattle

    GAITHERSBURG, Maryland, June 7, 2012—GenVec, Inc. (NASDAQ: GNVC) today announced that the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) has issued a conditional license for GenVec's foot-and-mouth disease (FMD) vaccine for use in cattle. APHIS issued the conditional license to Antelope Valley Bios, Inc., who manufactured the vaccine under a contract from GenVec. The vaccine was developed and tested under a contract with the U.S. Department of Homeland Security's Science and Technology Directorate. This is the first FMD vaccine licensed by the USDA Center for Veterinary Biologics.

    "This conditional approval is a significant event as it represents GenVec's first approved product," noted Bryan T. Butman, PhD, GenVec's senior vice president of Vector Operations and the head of GenVec's FMD program. "This achievement demonstrates GenVec's ability to bring its technology through the regulatory review process and validates the utility of our core technology to make effective genetic vaccines."

    The FMD vaccine, initially discovered and tested by the USDA Agricultural Research Service (ARS), was developed by GenVec scientists in collaboration with the DHS S&T Directorate's Targeted Advanced Development Branch at Plum Island Animal Disease Center.

    GenVec's novel FMD vaccine approach utilizes GenVec's proprietary adenovector technology and is manufactured on a proprietary GenVec cell line that is capable of producing antigens without the use of the highly contagious FMD virus. Because the vaccine is produced without using live or killed virus materials, it can be produced cost effectively in the U.S. and around the world.

    Under the conditional license, the product may be distributed as authorized by federal emergency management officials within USDA, should the need for the product arise.  APHIS issues conditional licenses in the event of an emergency situation, limited market, or other special circumstance. In this case, the special circumstance was the need for an FMD vaccine that was capable of being manufactured in the U.S. that allowed for the differentiation between infected and vaccinated animals. The vaccine will now be available to agriculture officials in the event of an FMD emergency situation.

    In a related, but separate effort, GenVec has licensed to Merial, the animal health division of Sanofi, the rights to develop and commercialize GenVec's proprietary vaccine technology for use against foot-and-mouth disease in cattle.

    About GenVec
    GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create therapeutics and vaccines. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health, we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com.

    Source: GenVec

    didyouknow

    Did you know... Ixodes spp ticks are thought to have expanded their range northward into areas previously too cold to maintain their populations.Read More

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More
    Subscribe